Although gliptins and incretin mimetics ultimately provide their pharmacological action through the same mechanism, the GLP-1/GIP receptors, their combination is not recommended in T2DM as it does not provide any clinically meaningful improvement in glycemic control over either agent singly [77, 78]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.